ArticleAME case reports2026
The development of intrapulmonary shunting caused by luspatercept in low grade myelodysplastic syndrome: a case report.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cytopenias are the hallmark manifestation of myelodysplastic syndrome (MDS) as patients frequently suffer from transfusion-dependent anemia. Luspatercept is part of a new family of drugs approved for transfusion-dependent MDS that bind transforming growth factor-β (TGF-β) family ligands to decrease SMAD signaling, resulting in an increase of circulating mature red cells. However, disruption of the TGF-β/SMAD pathway carries risks given its wide-ranging influence on the development and structure of blood vessels. Here we present the case of a patient with MDS presenting with refractory hypoxia from an intrapulmonary shunt secondary to the development of microvascular pulmonary arteriovenous malformations (PAVM) after starting luspatercept. Case Description: The patient reported progressive shortness of breath while receiving luspatercept and was eventually referred to a pulmonary clinic who discovered the shunt via a bubble echocardiogram. A broad cardiac and autoimmune work-up was unremarkable. Her hypoxia was out of proportion to spirometric and imaging findings. A computed tomography (CT) pulmonary angiogram did not reveal any large vascular malformations. Conclusions: The decision was made to stop the drug and her hypoxemia resolved within weeks in parallel with resolution of the shunt as the patient returned to room air and her prior functional baseline. In this report, the complex mechanism of luspatercept is discussed with a literature review on the clinical trials leading to its approval in MDS patients. Furthermore, we connect the pathophysiology between the formation of this patient's telangiectasias leading to her PAVM with the disruption of the TGF-β/SMAD pathway from luspatercept use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.